Multiple sclerosis drug pipeline

The examples and perspective in this article may not represent a worldwide view of the subject. You may improve this article, discuss the issue on the talk page, or create a new article, as appropriate. (September 2020) (Learn how and when to remove this message)

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.

Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate.

Pharmaceuticals already on the market, such as vitamin D, do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such drugs implies neither efficacy nor lack of efficacy.

In general, novel pharmaceuticals cannot enter a market without government approval; standards and political influences vary.